Compare GKOS & AMKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GKOS | AMKR |
|---|---|---|
| Founded | 1998 | 1968 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 8.5B |
| IPO Year | 2015 | 1997 |
| Metric | GKOS | AMKR |
|---|---|---|
| Price | $238.12 | $34.15 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 11 |
| Target Price | ★ $243.85 | $65.70 |
| AVG Volume (30 Days) | 1.5M | ★ 4.9M |
| Earning Date | 10-28-2026 | 10-26-2026 |
| Dividend Yield | N/A | ★ 0.95% |
| EPS Growth | N/A | ★ 4.90 |
| EPS | N/A | ★ 1.79 |
| Revenue | $507,442,000.00 | ★ $4,052,650,000.00 |
| Revenue This Year | $53.82 | $12.23 |
| Revenue Next Year | $28.56 | $14.14 |
| P/E Ratio | ★ N/A | $19.29 |
| Revenue Growth | ★ 32.33 | N/A |
| 52 Week Low | $93.78 | $30.03 |
| 52 Week High | $255.19 | $96.68 |
| Indicator | GKOS | AMKR |
|---|---|---|
| Relative Strength Index (RSI) | 59.90 | 40.08 |
| Support Level | $147.72 | $30.73 |
| Resistance Level | $255.19 | $51.89 |
| Average True Range (ATR) | 11.84 | 2.34 |
| MACD | -1.49 | 0.34 |
| Stochastic Oscillator | 43.31 | 39.91 |
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Amkor Technology Inc is a OSAT (outsourced semiconductor assembly and test) service provider. It has pioneered the outsourcing of integrated circuit (IC) packaging and test services and is a strategic manufacturing partner for the semiconductor companies, foundries, and electronics original equipment manufacturers (OEMs). The firm's products are organized into two categories namely advanced products that include flip chip, fine pitch bumping, wafer-level processing, advanced SiPs, power modules, and others, and Mainstream products that includes wirebond packaging and testing. The company derives maximum revenue from the advanced products category. The company derives majority of its revenue from Foreign states.